Skip to main content

Table 1 Characteristics of included studies

From: Meta-analysis of Nicorandil effectiveness on myocardial protection after percutaneous coronary intervention

Author, year

Samplesize, gender M/F

Mean age, years (SD)

Study population

NIC interventions

Control interventions

Outcome measures

Follow-up

Akagi, 2006 [21]

NIC: 10,6/4; 10,5/5

Control: 10,9/1

68 (9)

63 (15)

61(9)

Patients with AMI

IV drip infusion (4 mg/hr) before PCI for 48 h, 2 mg IC, and/not oral 15 mg/dayafter PCI

No NIC administered

LVEF

3 months

Chen, 2015 [22]

NIC: 26,18/8

Control: 26,19/7

57.6 (4.7)

59.8 (4.8)

Patients with AMI

IC2 mg before PCI

No NIC administered

LVEF; CK-MB; cTnI; MACEs

1 months

Fujiwara 2006 [23]

NIC: 31,25/6

Control: 31,25/6

62 (2)

62 (2)

Patients with AMI

4 mg IV before PCI, IV drip infusion (8 mg/hr) for 24 h after PCI

No NIC administered

LVEF

6 months

Hwang, 2013 [25]

NIC: 41,20/21

Control: 40,25/15

66.2 (9)

65.3 (10)

Patients with angina

IC 4 mg before PCI

No NIC administered

CK-MB; cTnI

NR

Ishii, 2005 [15]

NIC: 185,144/41

Control: 183,154/29

63 (9.4)

64 (10.1)

Patients with MI

12 mg IV over 20–30 min before reperfusion with PCI

Placebo

MACEs

5 years

Isono, 2008 [16]

NIC: 23,19/4

Control: 26,21/5

66.3 (7.9)

66.5 (9.4)

Patients with CHD

4 mg IV before PCI, IV drip infusion (6 mg/hr) for 24 h,oral15 mg/day3–6 months after PCI

No NIC administered

LVEF; CK-MB; cTnI

3 months

Ito, 1999 [17]

NIC: 40,32/8

Control: 41,32/9

60 (10)

60 (10)

Patients with first anterior AMI

4 mg IV before PCI, IV drip infusion (6 mg/hr) for 24 h,oral15 mg/day until the discharge (a mean of 28 days) after PCI

No NIC administered

LVEF; MACEs

6 months

Kawai, 2009 [18]

NIC: 206,161/45

Control: 202,149/53

69 (11.1)

71 (11.5)

Patients with/without acute coronary syndrome

6 mg IV before PCI

No NIC administered

CK-MB;MACEs

12 months

Kim, 2005 [24]

NIC: 42,27/15

Control: 54,32/22

60.4 (11.7)

61.7 (8.2)

Patients with unstable angina

4 mg IV before PCI, IV drip infusion (6 mg/hr) for 48 h,oral15 mg/day6 months after PCI

Isosorbide dinitrate

LVEF; MACEs

6 months

Kim, 2012 [19]

NIC: 54,36/8

Control: 55,46/9

65.5 (7.4)

63.2 (9.2)

Patients with stable or unstable angina

4 mg ICin 5 min before PCI

No NIC administered

MACEs

6 months

Miyoshi, 2017 [13]

NIC: 129,99/30

Control: 133,102/31

70.0 (9.2)

70.3 (10.1)

Patients with stable coronary artery disease

4 mg IV for 5 min at least 1 h before PCI, IV drip infusion (6 mg/h) for at least 8 h after PCI

No NIC administered

MACEs

8 months

Murakami, 2006 [26]

NIC: 91,75/16

Control: 101,81/20

65.0 (9.7)

66.1 (10.3)

Patients with CHD

IV drip infusion (2 mg/h) for 6 h after PCI

Placebo

CK-MB;cTnI

3 months- 3.1 years

Ono, 2004 [20]

NIC: 33,22/11

Control: 25,16/9

64 (13)

66 (12)

Patients with AMI

4 mg IV before PCI, IV drip infusion (8 mg/hr) for 24 h after PCI

No NIC administered

LVEF; MACEs

6 months

Yamada, 2015 [14]

NIC: 28,23/5

Control: 24,22/2

67 (10)

65 (12)

Patients with AMI

2 mg IC before PCI, IV drip infusion (2 mg/hr) for 4 days after PCI

Nitrate

LVEF

NR

  1. NIC Nicorandil, IC intracoronary, IV intravenous, CHD coronary heart disease, AMI Acute myocardial infarction, LVEF Left ventricular ejection fraction, CK-MB creatine kinase-MB, cTnI troponin I, MACEs major adverse cardiovascular events,NR Not reported